Association of Resistin Gene Polymorphisms with Oral Squamous Cell Carcinoma Progression and Development

Table 4

Associations between the RETN rs3219175 polymorphism and clinical status in men aged >54 years with OSCC.

	Clinical Stage		OR (95% CI)	AOR (95% CI)
RETN rs3219175	Stage I/II (n=243)	Stage III/IV (n=239)
GG	160 (65.8%)	150 (62.8%)	1.000 (reference)	1.000 (reference)
GA	74 (30.5%)	73 (30.5%)	1.052 (0.711-1.558)	1.030 (0.693-1.529)
AA	9 (3.7%)	16 (6.7%)	1.896 (0.813-4.421)	1.896 (0.808-4.452)
	Tumor size
RETN rs3219175	T2 (n=272)	> T2 (n=210)
GG	181 (66.5%)	129 (61.4%)	1.000 (reference)	1.000 (reference)
GA	82 (30.2%)	65 (31.0%)	1.112 (0.748-1.653)	1.113 (0.747-1.658)
AA	9 (3.3%)	16 (7.6%)	2.494 (1.069-5.820)	2.480 (1.058-5.814)
	Lymph node metastasis
RETN rs3219175	No (n=333)	Yes (n=149)
GG	215 (22.8%)	95 (63.8%)	1.000 (reference)	1.000 (reference)
GA	102 (54.5%)	45 (30.2%)	0.998 (0.652-1.528)	0.969 (0.631-1.488)
AA	16 (22.7%)	9 (6.0%)	1.273 (0.543-2.983)	1.240 (0.525-2.930)
	Metastasis
RETN rs3219175	M0 (n=477)	M1 (n=5)
GG	308 (64.6%)	2 (40.0%)	1.000 (reference)	1.000 (reference)
GA	144 (30.2%)	3 (60.0%)	3.208 (0.530-19.411)	3.009 (0.491-18.451)
AA	25 (5.2%)	0 (27.2%)	-	0.783 (0.172-3.559)
	Cell differentiation
RETN rs3219175	Well (n=76)	Moderate/poor (n=406)
GG	51 (67.1%)	259 (63.8%)	1.000 (reference)	1.000 (reference)
GA	21 (27.6%)	126 (31.0%)	1.181 (0.681-2.050)	1.176 (0.675-2.047)
AA	4 (5.3%)	21 (5.2%)	1.034 (0.340-3.139)	0.963 (0.315-2.945)

Multivariate analysis adjusted for the effects of betel quid chewing, tobacco smoking, and alcohol consumption.
p = 0.0345; p = 0.0367.